# Nuvation Bio

Nuvation Bio is an Asset Manager based in New York, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** 1500 Broadway, Suite 1401, New York, NY 10036, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** nuvationbio.com
- **LinkedIn:** https://www.linkedin.com/company/nuvationbio

## Regulatory record

- **Reports private funds:** No

## About

Discover Nuvation Bio, Inc., a leader in oncology drug development. Learn about our innovative pipeline and commitment to transforming cancer treatment.

## Sectors

- Oncology
- Biotechnology

## Offices

- San Francisco, CA, United States
- Burlington, MA, United States
- Shanghai, China
- Beijing, China
- Hangzhou, China

## People

- David Hung — Founder, President, and Chief Executive Officer

## Questions

### Who leads Nuvation Bio, and what is his track record?

David Hung founded Nuvation Bio in 2018 and serves as president and CEO. He previously founded Medivation, which developed the prostate-cancer drug enzalutamide and was acquired by Pfizer for approximately $14 billion in 2016. Hung's role at Nuvation Bio combines strategic capital allocation with direct oversight of the pipeline that targets cancers with few remaining treatment options.

### What is Nuvation Bio's investment stage and asset-class focus?

The firm operates exclusively in clinical-stage oncology, advancing small-molecule and biologic drug candidates through human trials. Nuvation Bio transitioned from pure clinical development to commercial-stage in 2025, meaning at least one product now generates revenue. The company does not invest in third-party venture funds, real estate, or non-biotech sectors.

### How does Nuvation Bio access the Chinese market?

Nuvation Bio maintains three China-based offices — in Shanghai, Beijing, and Hangzhou — that support clinical trials, regulatory engagement, and operational execution. This dual-jurisdiction setup enables parallel development under both US FDA and China NMPA frameworks, a structural feature most small-cap US biotechs lack.

### What was the operational milestone Nuvation Bio hit most recently?

In 2025, Nuvation Bio became a commercial-stage company, shifting its financial profile from preclinical R&D to marketed-product revenue. The firm commemorated the transition by ringing the closing bell at the New York Stock Exchange.

## Related profiles

- [GBT Travel Services UK Limited](https://altss.com/profile/gbt-travel-services-uk-limited)
- [Fairstone Financial Inc.](https://altss.com/profile/fairstone-financial-inc-home-capital-group-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/nuvation-bio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology